Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
The study's authors noted that the ECG acquisition technology in these wearable devices appears to be quite effective. The automated algorithms, however, could still be improved.
The four-year analysis will use cardiac MRI scans to closely monitor the heart health of people living with HIV who regularly use cannabis to treat their symptoms.
The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.
Ultrasounds of fetuses who later developed ASD displayed three times more anatomical anomalies than the general population control group, according to research in Brain.
“For decades, the patients in our group have testified that they don’t feel they’ve recovered, and we hope our study will provide further clues about what happens in the brain,” experts involved in the study said.
The new guideline calls for a “stepwise approach," followed by close clinical surveillance, when treating uncomplicated TBAD. In some cases, however, earlier endovascular treatments may be necessary.
